NewAmsterdam Pharma Company ( (NAMS) ) has shared an update.
NewAmsterdam Pharma unveiled promising outcomes from its Phase 3 BROOKLYN trial, showcasing the potential of obicetrapib to significantly lower LDL-C and other cardiovascular risk markers in patients with heterozygous familial hypercholesterolemia. Achieving a notable 36.3% reduction in LDL-C compared to placebo, obicetrapib also demonstrated impressive results across secondary markers like Lp(a) and ApoB, while maintaining a safety profile akin to placebo. These results underscore obicetrapib’s potential to address unmet needs in lipid management and support its future as a pivotal cardiovascular treatment option.
Learn more about NAMS stock on TipRanks’ Stock Analysis page.